The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PARD | +0% | -99.89% | -74.21% | -100% |
| S&P | +12.65% | +91.73% | +13.89% | +2,461% |
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of oncology products. The company is currently focusing on developing picoplatin, a new and differentiated platinum-based chemotherapeutic agent that is used in the clinical development for multiple cancer indications, treatment combinations, and by different routes of administration. The company was founded in 1984 and is headquartered in Seattle, WA.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
